Literature DB >> 11302238

Diffusion of reduced arecoline and arecaidine through human vaginal and buccal mucosa.

A D Van Eyk, C W Van Wyk, I A Stander.   

Abstract

Because alkaloids from areca nut, arecoline and arecaidine, have been implicated in the development of oral submucous fibrosis, we determined their diffusion kinetics through human buccal and vaginal mucosa. Four clinically healthy vaginal mucosa specimens (mean patient age +/- standard deviation: 47 +/- 15 years; age range: 31-60 years) and 4 buccal mucosa specimens from 2 male patients and 2 female patients (mean patient age +/- standard deviation: 31 +/- 9 years; age range: 17-53 years) were obtained during surgery. In vitro flux rates of reduced arecoline and arecaidine (r-arecoline and r-arecaidine) were determined by use of a flow-through diffusion apparatus. Analysis of variance, a Duncan multiple range test, and an unpaired t-test were used to determine steady state kinetics and flux differences over time intervals. Although statistically significant differences were observed between flux values for both alkaloids and tissues at certain time points, these were not considered to be of biological (clinical) significance. However, the flux rates across both mucosa of r-arecoline were significantly higher statistically than those of rarecaidine. The findings demonstrated the differences in the diffusion kinetics between r-arecoline and r-arecaidine across human buccal and vaginal mucosa, an observation that could be explained in terms of their ionisation characteristics. Additionally, the results obtained further support the hypothesis that human vaginal mucosa can be used as a model for buccal mucosa in studies of permeability to various chemical compounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302238     DOI: 10.1034/j.1600-0714.2001.300402.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  6 in total

1.  Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells.

Authors:  Shuei-Kuen Tseng; Mei-Chi Chang; Cheng-Yao Su; Lin-Yang Chi; Jenny Zwei-Ching Chang; Wan-Yu Tseng; Sin-Yuet Yeung; Ming-Lun Hsu; Jiiang-Huei Jeng
Journal:  Clin Oral Investig       Date:  2011-08-17       Impact factor: 3.573

2.  New Insights for Consummate Diagnosis and Management of Oral Submucous Fibrosis Using Reactive and Reparative Fibrotic Parameter Derived Algorithm.

Authors:  Ramya Ramadoss; Rajkumar Krishnan; V Vasanthi; Divya Bose; R Vijayalakshmi; Rajashree Padmanabhan; Balakumar Subramanian
Journal:  J Pharm Bioallied Sci       Date:  2021-06-05

3.  Study of salivary arecoline in areca nut chewers.

Authors:  Deepak Venkatesh; R S Puranik; S S Vanaki; Surekha R Puranik
Journal:  J Oral Maxillofac Pathol       Date:  2018 Sep-Dec

4.  Phenotypic Expression of Oral Fibroblasts Derived from Oral Submucous Fibrosis: An Assay through Cell Culture.

Authors:  Abhishek Banerjee; Mathew O Mampilly; V V Kamath; Vijayaraghavan Athreya; Vijayalakshmi Kotrashetti; Kumar Chandan Srivastava; Deepti Shrivastava
Journal:  J Pharm Bioallied Sci       Date:  2021-11-10

5.  Fucoidan-Mediated Inhibition of Fibrotic Properties in Oral Submucous Fibrosis via the MEG3/miR-181a/Egr1 Axis.

Authors:  Chih-Yuan Fang; Szu-Han Chen; Chun-Chung Huang; Yi-Wen Liao; Shih-Chi Chao; Cheng-Chia Yu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-05

6.  Arecoline induces TNF-alpha production and Zonula Occludens-1 redistribution in mouse Sertoli TM4 cells.

Authors:  Tzer-Min Kuo; Shun-Yuan Luo; Shang-Lun Chiang; Chi-Pin Lee; Yu-Fan Liu; Jan-Gowth Chang; Ming-Hsui Tsai; Ying-Chin Ko
Journal:  J Biomed Sci       Date:  2014-09-09       Impact factor: 8.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.